Perceived comfort with migraine treatments and control of migraine symptoms: Results from the Headache Assessment via Digital Platform in United States study.

This study aimed to identify factors influencing comfort with migraine treatments. It involved participants from the Headache Assessment via Digital Platform in the United States. The study found that 58% of participants reported high comfort with their treatments. However, only 28% felt high control over their migraine symptoms. High comfort correlated with fewer monthly headache days and lower symptom severity. For instance, those reporting high comfort experienced about 9.9 headache days compared to 14.2 for those with low comfort. Similarly, high perceived control was linked with lower headache days and migraine severity. Medication class also played a role in comfort. Gepants and triptans were associated with higher comfort and efficacy. In contrast, β blockers and botulinum toxin were rated least favorably. The findings highlight the need to consider patient perspectives in treatment planning. Addressing mood and disability can improve outcomes for those with migraines. Clinical relevance: This research emphasizes the importance of patient comfort and control when selecting migraine treatments.